About BIOPHYTIS BSA
Sector
CEO
Stanislas Veillet
Headquarters
Paris
Website
Founded
2006
ISIN
FR0013507290
FIGI
BBG00THVR2T4
Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 27, 2006 and is headquartered in Paris, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
